Retatrutide's ADA data lands as the Medicare tailwind arrives

Eli Lilly presented data on its experimental drug retatrutide at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, the industry's biggest research meeting of the year ^[2]. The company's Phase 3 TRIUMPH-1 trial found that patients with obesity but without diabetes lost 28.3% of their body weight over 80 weeks, a result Lilly has compared to outcomes seen after bariatric surgery ^[2]. Retatrutide is not yet approved; it remains in late-stage testing, with Lilly telling investors it plans to file for FDA approval in the first quarter of 2027 after two more Phase 3 studies, TRIUMPH-2 and TRIUMPH-3, read out in July 2026 ^[1].

Retatrutide works differently than the GLP-1 drugs already on the market. It targets three hormone pathways at once — GLP-1, GIP, and glucagon — which Lilly has described as a "different drug category" from its existing products, tirzepatide (Mounjaro and Zepbound) and the oral pill Foundayo (orforglipron), according to William Blair analyst Andy Hsieh ^[2]. But the added potency has come with a tradeoff. In a separate Phase 3 study, TRIUMPH-4, which enrolled people with obesity or who were overweight along with knee osteoarthritis, Lilly reported 26.6% placebo-adjusted weight loss at 68 weeks but also flagged a safety signal called dysesthesia — an abnormal, sometimes unpleasant sensation on the skin — in more than a fifth of patients taking the highest, 20-milligram dose ^[2]. That signal also appeared in TRIUMPH-1, with rates rising as the dose increased ^[2].

The timing matters because Lilly is defending a lead position. Its tirzepatide and orforglipron franchise already drove $23.0 billion in second-quarter 2026 revenue, up 48% from a year earlier, and the company raised its full-year sales guidance to $85–87 billion in early August ^[1]. Novo Nordisk, Lilly's chief rival, brought its own next-generation candidate, CagriSema, to the same ADA meeting, but a head-to-head study released in February found CagriSema produced 23% average weight loss at 84 weeks compared with 25.5% for Zepbound, a result Novo's CEO said still positions the drug to carry "the best weight loss label than any product marketed at that time" once it reaches pharmacies ^[2].

The development summary references a Medicare coverage change, described as a "GLP-1 Bridge," opening around the same time as the ADA presentations. That specific Medicare program is not described in the sources reviewed for this story, so its details, eligibility rules, and effective date are not yet known from the available reporting.

Why it matters for patients

Retatrutide is not available to patients today. It remains an investigational drug going through Phase 3 trials, and Lilly has not yet filed for FDA approval, which it has said will happen no earlier than the first quarter of 2027 ^[1]. Patients currently on tirzepatide, semaglutide, or orforglipron will not see any near-term change in access or dosing because of this data release.

The dysesthesia signal is worth watching. Because rates rose with higher doses in both TRIUMPH-1 and TRIUMPH-4, tolerability — not just weight-loss numbers — will likely shape how retatrutide is eventually positioned if it reaches the market ^[2]. Analysts have said the debate over the drug will center on this tradeoff between higher efficacy and side effects ^[2].

What happens next

TRIUMPH-2 and TRIUMPH-3, the remaining Phase 3 studies of retatrutide, were guided to read out on July 23, 2026 ^[1]. Lilly has said it expects to file a Biologics License Application with the FDA in the first quarter of 2027 ^[1]. Any Medicare coverage changes referenced alongside this data have not been detailed in available sources and should be confirmed through official Medicare or CMS announcements as they emerge.